RxDoctor Payments DataLook up a doctor →

Ann Hyatt, MD

Dermatology · Indianapolis, INNPI 1265691232

Payments from drug & device makers

$13,448in general payments, 2019–2025

Across 897 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novartis$2K
  • Lilly USA, LLC$1K
  • Pfizer$987
  • Johnson & Johnson$978
  • Incyte Corporation$806
  • plus $5K from 28 others

What the payments were for

  • Food & beverage$13,08297%
  • Education$3653%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,448 in reported general payments places this provider in the 80th percentile of 202 dermatology providers in Indiana.

See all dermatology providers in Indiana

Medicare billing

Part B allowed, 2024
$1,122,537
Medicare patients
4,105
Services billed
12,820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$297,315
Dupixent PenDupilumab75$282,694
Cosentyx Sensoready (2 Pens)Secukinumab27$225,451
Humira(Cf) PenAdalimumab23$157,548
OtezlaApremilast33$154,895
Taltz AutoinjectorIxekizumab18$134,773
Dupixent SyringeDupilumab32$118,492
XolairOmalizumab12$37,238
VtamaTapinarof12$16,839
Clobetasol Propionate213$10,406
Ketoconazole418$5,546
Fluorouracil81$4,993
Fluocinonide136$4,924
Tacrolimus36$4,314
Clindamycin Phosphate70$3,389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$978$297,31512 claims
AmgenOtezla$701$154,89533 claims
Dermavant Sciences, Inc.Vtama$400$16,83912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 202 dermatology providers in Indiana.

Other dermatology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →